FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2616559663> ?p ?o ?g. }

• W2616559663 endingPage "1013" @default.
• W2616559663 startingPage "1007" @default.
• W2616559663 abstract "Objectives: To evaluate the tolerance and effectiveness of stereotactic ablative radiotherapy (SABR) applied in the treatment of low and intermediate risk (LR & IR) prostate cancer patients (PCP) and provide an evaluation of the level of risk group impact on treatment results. In addition, androgen deprivation therapy (ADT) usage and prostatic specific antigen (PSA) decline after SABR were assessed. Material and Methods: A total of 400 PCP (213 LR and 187 IR, including T2c) were irradiated with a CyberKnife using fd 7.25 Gy to TD 36.25 Gy. At the start of treatment, 60.3% of patients were undergoing ADT and this gradually decreased to 0% after 38 months. Follow-up was for a median of 15.0 months. Patients were monitored on SABR completion and 1, 4, 8 months later and then subsequently every 6 months. GI (Gastro-Intestinal) and GU (Genito-Urinary) acute and late adverse effects, PSA and ADT usage were evaluated. Results: Failure was noted in 9 patients (2.25%) (5 in LR and 4 in IR groups) - 4 relapses and 5 nodal metastases. No G3/4 late adverse effects (EORTC/RTOG) were observed. Some 0.5% of G3 GU and 0.3% of G3 GI acute reactions were noted respectively on the SABR completion day and one month later. The median of PSA declined 1.5 ng/ml during the first month and 0.6 ng/ml during the next three months. No impact of risk groups on treatment results was found. An impact of ADT on PSA decline was only confirmed for time point interactions. Conclusions: SABR for LR and IR PCP is a safe and effective treatment. The inclusion of T2c patients and the low percentage of IR patient failure permit us the assumption that this procedure could be utilized in the treatment of more advanced cases. The results do not allow clear definition of the impact of ADT on radioablation results in LR and IR+ T2c cases." @default.
• W2616559663 created "2017-05-26" @default.
• W2616559663 creator A5056127775 @default.
• W2616559663 creator A5064120794 @default.
• W2616559663 creator A5069140426 @default.
• W2616559663 creator A5071051754 @default.
• W2616559663 creator A5075389870 @default.
• W2616559663 creator A5079600753 @default.
• W2616559663 creator A5085223650 @default.
• W2616559663 date "2017-04-01" @default.
• W2616559663 modified "2023-10-01" @default.
• W2616559663 title "Cyberknife Radioablation of Prostate Cancer – Preliminary Results for 400 Patients" @default.
• W2616559663 cites W1874355795 @default.
• W2616559663 cites W1975043846 @default.
• W2616559663 cites W1995785545 @default.
• W2616559663 cites W2030378684 @default.
• W2616559663 cites W2065848035 @default.
• W2616559663 cites W2079498177 @default.
• W2616559663 cites W2089324819 @default.
• W2616559663 cites W2092374102 @default.
• W2616559663 cites W2094442174 @default.
• W2616559663 cites W2099589368 @default.
• W2616559663 cites W2115307735 @default.
• W2616559663 cites W2127644635 @default.
• W2616559663 cites W2130689870 @default.
• W2616559663 cites W2134991001 @default.
• W2616559663 cites W2135257055 @default.
• W2616559663 cites W2146554480 @default.
• W2616559663 cites W2148117492 @default.
• W2616559663 cites W2167080855 @default.
• W2616559663 cites W2171769598 @default.
• W2616559663 cites W2187035960 @default.
• W2616559663 cites W2191094045 @default.
• W2616559663 cites W2245551075 @default.
• W2616559663 cites W2318410370 @default.
• W2616559663 cites W2337386322 @default.
• W2616559663 cites W2409858137 @default.
• W2616559663 cites W2415025972 @default.
• W2616559663 cites W2438113634 @default.
• W2616559663 cites W2469323349 @default.
• W2616559663 cites W2479508725 @default.
• W2616559663 cites W2488203186 @default.
• W2616559663 cites W2509480329 @default.
• W2616559663 cites W2514885793 @default.
• W2616559663 cites W2296418721 @default.
• W2616559663 doi "https://doi.org/10.22034/apjcp.2017.18.4.1007" @default.
• W2616559663 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5494208" @default.
• W2616559663 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28545199" @default.
• W2616559663 hasPublicationYear "2017" @default.
• W2616559663 type Work @default.
• W2616559663 sameAs 2616559663 @default.
• W2616559663 citedByCount "4" @default.
• W2616559663 countsByYear W26165596632019 @default.
• W2616559663 countsByYear W26165596632021 @default.
• W2616559663 countsByYear W26165596632022 @default.
• W2616559663 crossrefType "journal-article" @default.
• W2616559663 hasAuthorship W2616559663A5056127775 @default.
• W2616559663 hasAuthorship W2616559663A5064120794 @default.
• W2616559663 hasAuthorship W2616559663A5069140426 @default.
• W2616559663 hasAuthorship W2616559663A5071051754 @default.
• W2616559663 hasAuthorship W2616559663A5075389870 @default.
• W2616559663 hasAuthorship W2616559663A5079600753 @default.
• W2616559663 hasAuthorship W2616559663A5085223650 @default.
• W2616559663 hasConcept C106159729 @default.
• W2616559663 hasConcept C121608353 @default.
• W2616559663 hasConcept C126322002 @default.
• W2616559663 hasConcept C126894567 @default.
• W2616559663 hasConcept C162324750 @default.
• W2616559663 hasConcept C187625094 @default.
• W2616559663 hasConcept C197934379 @default.
• W2616559663 hasConcept C2776235491 @default.
• W2616559663 hasConcept C2776651944 @default.
• W2616559663 hasConcept C2777899217 @default.
• W2616559663 hasConcept C2780192828 @default.
• W2616559663 hasConcept C2780387249 @default.
• W2616559663 hasConcept C2781406297 @default.
• W2616559663 hasConcept C509974204 @default.
• W2616559663 hasConcept C71924100 @default.
• W2616559663 hasConcept C85393063 @default.
• W2616559663 hasConcept C91602232 @default.
• W2616559663 hasConceptScore W2616559663C106159729 @default.
• W2616559663 hasConceptScore W2616559663C121608353 @default.
• W2616559663 hasConceptScore W2616559663C126322002 @default.
• W2616559663 hasConceptScore W2616559663C126894567 @default.
• W2616559663 hasConceptScore W2616559663C162324750 @default.
• W2616559663 hasConceptScore W2616559663C187625094 @default.
• W2616559663 hasConceptScore W2616559663C197934379 @default.
• W2616559663 hasConceptScore W2616559663C2776235491 @default.
• W2616559663 hasConceptScore W2616559663C2776651944 @default.
• W2616559663 hasConceptScore W2616559663C2777899217 @default.
• W2616559663 hasConceptScore W2616559663C2780192828 @default.
• W2616559663 hasConceptScore W2616559663C2780387249 @default.
• W2616559663 hasConceptScore W2616559663C2781406297 @default.
• W2616559663 hasConceptScore W2616559663C509974204 @default.
• W2616559663 hasConceptScore W2616559663C71924100 @default.
• W2616559663 hasConceptScore W2616559663C85393063 @default.
• W2616559663 hasConceptScore W2616559663C91602232 @default.
• W2616559663 hasIssue "4" @default.

• next